Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | PIR | O00625 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 4/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2938712 | 1.00 | CYP2C19 (0.54) | CYP2C19PIRF2PRSS1PRSS2 | |
| SCHEMBL1774767 | 1.00 | CYP2C19 (0.54) | CYP2C19PIRF2PRSS1PRSS2 | |
| SCHEMBL1774411 | 0.90 | CYP2C19 (0.65) | CYP2C19PIRF2PRSS1PRSS2 | |
| SCHEMBL1774413 | 0.90 | CYP2C19 (0.65) | CYP2C19PIRF2PRSS1PRSS2 | |
| SCHEMBL2935232 | 0.90 | CYP2C19 (0.65) | CYP2C19PIRF2PRSS1PRSS2 | |
| SCHEMBL1775481 | 0.85 | CYP2C19 (0.77) | CYP2C19PIRF2PRSS1PRSS2 | |
| SCHEMBL2937262 | 0.85 | CYP2C19 (0.77) | CYP2C19PIRF2PRSS1PRSS2 | |
| SCHEMBL1775480 | 0.85 | CYP2C19 (0.77) | CYP2C19PIRF2PRSS1PRSS2 | |
| SCHEMBL14355817 | 0.83 | CYP2C19 (0.56) | CYP2C19PIRF2PRSS1PRSS2 | |
| SCHEMBL17020444 | 0.83 | CYP2C19 (0.79) | CYP2C19PIRF2PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943629-B2 | Anticancer/antitumor agents; S-(4-([4-([(1R,2R)-2-Hydroxy-1-methylpropyl]amino)-5-(trifluoromethyl)-pyrimidin-2-yl]amino)phenyl)-S-methyl-N-[(trifluoromethyl)sulphonyl]-sulphimide for example | BAYER SCHERING PHARMA AG (DE) | 2011-05-17 | — | — | US | disclosed |
| US-7943629-B2 | Anticancer/antitumor agents; S-(4-([4-([(1R,2R)-2-Hydroxy-1-methylpropyl]amino)-5-(trifluoromethyl)-pyrimidin-2-yl]amino)phenyl)-S-methyl-N-[(trifluoromethyl)sulphonyl]-sulphimide for example | BAYER SCHERING PHARMA AG (DE) | 2011-05-17 | — | — | US | disclosed |
| EP-2029552-B1 | SULFIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2010-09-22 | — | — | EP | disclosed |
| EP-2029552-B1 | SULFIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2010-09-22 | — | — | EP | disclosed |
| EP-2029552-A1 | SULFIMIDES AS PROTEIN KINASE INHIBITORS | Bayer Schering Pharma AG (DE) | 2009-03-04 | — | — | EP | disclosed |
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
| WO-2007140957-A1 | SULFIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007140957-A1 | SULFIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058358-A1 | SULPHIMIDES AS PROTEIN KINASE INHIBITORS | PRKCE, BRAF, PACSIN2 | CYP2C19 3401/4885PIR 3954/4885F2 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.